Towards a Paradigm Shift in the Treatment of Chronic Chagas Disease


Hospital Intezonal General de Agudos (HIGA) Eva Perón, Sección Chagas, Servicio de Cardiología, Buenos Aires, Argentina; Instituto de Medicina Tropical, Universidad Central de Venezuela (IMT-UCV), Caracas, Venezuela; Fundação Oswaldo Cruz—Instituto Oswaldo Cruz (FIOCRUZ-IOC), Programa Integrado de Doenças de Chagas, Laboratório de Inovações em Terapias, Ensino e Bioproductos, Rio de Janeiro, Brazil; Centro de Investigación de Enfermedades Infecciosas de la Pontificia Universidad Católica del Ecuador (CIE-PUCE), Quito, Ecuador, and Tropical Disease Institute, Ohio University (TDI-OU), Athens, Ohio, USA; Centro de Investigaciones en Microbiología y Parasitología Tropical, Universidad de los Andes (UA-COMPAT), Bogotá, Colombia; Instituto de Parastrologia y Biomedicina Lopez-Neya-Consejo Superior de Investigaciones Científicas (IPBLN-CSIC), Granada, Spain; Centro Regional de Investigación en Salud Pública, Instituto Nacional de Salud Pública (CRISP-INSP), Tapachula, Chiapas, Mexico; Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland; Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI), CONICET, Buenos Aires, Argentina; Instituto Nacional de Parasitología Dr. Mario Fatala Chaben (INP)-ANLIS Dr. Carlos G. Malbran, Buenos Aires, Argentina; Universidad Mayor de San Simón (UMSS), Cochabamba, Bolivia, and Barcelona Center for International Health Research (CRESIB), Hospital Clinic/IDIBAPS, Barcelona, Spain

Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages) and for children up to 14 years old. The World Health Organization, however, also recommends specific antiparasite treatment for all chronic-phase *Trypanosoma cruzi*-infected individuals, even though in current medical practice this remains controversial, and most physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond parasitological cure. Etiological treatment should now be mandatory for all adult chronic Chagas disease patients.

There are an estimated 8 million chronic Chagas disease (CD) patients in Latin America (1), a large proportion of whom do not receive specific antiparasite treatment, and a growing infected population in the United States, Canada, and Europe (2). Antiparasitic treatment for Chagas disease (CD) is recommended universally for acute cases and for children up to 14 years old in most countries (3). Despite the inclusion of chronic patients in the guidelines, most doctors only prescribe symptomatic treatment of cardiomyopathy and digestive symptoms, avoiding antiparasitic drugs. At a meeting of clinical CD experts held in 1983, the use of etiological treatment for chronic stages was not recommended, pending more solid evidence of its efficacy (4) and of autoimmune mechanism involvement (5). Natural and elicited immunoglobulins and effector immune cells produced or modified during *Trypanosoma cruzi* infection can directly or indirectly affect heart tissue. There is no evidence that any putative autoimmune mechanisms, which may be secondary aggravating factors in the progression to cardiomyopathy, are primary causes of the chronic pathology (6). It is unclear, in addition, whether autoimmune reactions can be avoided if the infection is prevented or controlled (7), although it has been experimentally demonstrated that elimination of the parasite results in the reduction or elimination of autoimmune responses in the chronic phase of infection (8, 9).

In addition to neglecting adult chronic patient treatment by adopting the 1983 recommendations, the lack of even a tentative recommendation had a negative impact on the chronic patients’ perceptions regarding their illness. These patients are labeled as “chagasic” and not simply as *T. cruzi*-infected persons, leading to social stigma and negative economic and psychological effects from carrying a lethal, cureless, and disabling disease (10). A similar conflict between infection and disease existed for AIDS and leprosy. Chronic progression in both cases, similar to that in CD, evolves differentially in each patient, leading to a shift in current clinical management to the use of pathogen-specific treatments (3).

Scientific evidence regarding the role of the parasite, *Trypanosoma cruzi*, as a stimulus and trigger for tissue damage has accumulated over the last 2 decades, providing a solid basis to reconsider antiparasitic treatment for chronic adult patients. The present article reviews the evidence and presents arguments for antiparasitic treatment of adult chronic patients, representing the opinion of clinical and biomedical scientists of the NHEPACHA network and coinciding with international guidelines that now recommend offering treatment to these patients (3, 11, 12).

**PATHOGENESIS OF CHRONIC CHAGAS DISEASE: CHRONIC PERSISTENCE OF THE PARASITE?**

Following the acute phase of *T. cruzi* infection, CD patients evolve a chronic phase which is initially asymptomatic (indeterminate form of CD). This form of CD is defined by *T. cruzi* infection (positive parasitological and/or serological tests), the absence of clinical disease symptoms, and normal electrocardiogram (EKG), thorax radiography, and colonic/esophageal imaging tests. How...
ever, around 30% to 40% of chronically infected individuals will develop symptomatic disease over time (13). Biomarkers to follow each patient’s evolution are currently being developed, assessed, and standardized. Several studies have highlighted the key role of myocardial inflammation in the progressive fibrotic cardiomyopathy of chronic cardiac CD (14). Evidence for chronic persistence of infective parasites after the acute infection, both in areas where T. cruzi is endemic and where it is not, includes vertical transmission or transfusion and transplant transmission, which only occur if there are viable parasites in chronically infected mothers or blood/transplant donors (15,16). In addition, chronic persistence is evident from clinical reactivations of immune-depressed patients or transplanted or HIV-infected individuals (17, 18), by isolation of parasites through hemoculture of samples from chronically infected patients, and by detection of parasites in bug feces following xenodiagnosis. Parasites can be detected most sensitively in blood and tissues using molecular techniques (19) and have been documented in cardiac inflammatory tissues (20).

The pathogenesis of chronic CD is currently considered multifactorial, with as-yet poorly understood complex host-pathogen interactions. Several potential autoimmune mechanisms have been described (21), and good reviews and critiques of prevailing theories are available (22, 23). Although there is no doubt regarding the existence of an inflammatory immune response in CD, there is no conclusive experimental evidence that autoimmunity plays a significant role in its pathogenesis (7). Additional factors which may also play a role in chronic CD are microvascular disturbances and neurogenic lesions producing dysautonomy (24).

Overall, the prevailing evidence indicates that parasite persistence is fundamental for triggering and sustaining pathogenic processes (25).

### WHAT IS CONSIDERED EFFICACY: A LOWER PARASITE BURDEN OR PARASITE CLEARANCE?

Although the treatment goal for infectious diseases is or should be pathogen elimination, there are other equally important therapeutic outcomes to be considered (26). Control and reduction of the pathogen burden are well-recognized strategies for some infections, such as AIDS, which is now a classic example of a lethal infection which can convert into a chronically controlled disease with the administration of appropriate treatment.

Numerous studies in animal models and humans have reported the efficacy of parasitic treatment in both the acute and chronic phase of CD (8, 9, 27, 28), with two randomized studies having demonstrated the efficacy of benznidazole treatment in children (29, 30). Furthermore, other experimental studies have demonstrated a strong treatment impact on many immune response parameters, and these findings are consistent with parasite elimination or reduction (31, 32). One previous report and several subsequent nonrandomized studies have shown improved clinical and serological evolution for treatment with benznidazole compared with the same parameters in untreated chronic patients (26, 33–37). Numerous subsequent studies and evidence supporting etiologic treatment of chronic CD are summarized elsewhere (27), while Table 1 summarizes the results of etiologic treatment in chronic patients from four nonrandomized studies (38). These latter studies demonstrate better clinical evolution in antiparasite-treated patients. An association between clinical evolution and negative seroconversion has also been analyzed in these previous studies, as in a recent publication that reported 107 chronic adult patients with cure criteria (39).

Two randomized trials are in the process of comparing benznidazole to placebo in chronic patients. The first, including patients with or without mild heart disease, conducted in Argentina (TRAENA) and terminated in 2012, is currently being analyzed (40). The other is a multicenter study (BENEFIT) that should be completed by 2014 (41) and will provide evidence regarding the evolution of advanced or mild heart disease in chronic patients treated with antiparasitic drugs. The evolution of individuals with irreversible myocardial damage and, hence, at the clinical endpoint for trial evaluation may not be the same as for those who have not yet developed cardiomyopathy when they are each given antiparasitic treatment.

### TREATMENT MONITORING

Antiparasitic treatment efficacy in Chagas disease can only be measured currently using anti-T. cruzi antibody titers and/or by parasite detection in blood. A therapeutic failure is defined by the persistence of the parasite, detected using different methods, such as PCR, while treatment success would be measured by the absence or reduction of antibody titers. However, a reduction in T. cruzi-specific antibody titers often takes many years, rendering measurement of treatment success insensitive and lengthy.

A long-term follow-up study using qualitative PCR before and after treatment with benznidazole, conducted in a country where CD is not endemic (42), demonstrated two key findings. Sixty-eight percent of adults with chronic Chagas disease were PCR positive prior to treatment, and of these, 100% converted to PCR-negative prior to treatment, and of these, 100% converted to PCR-negative prior to treatment, and of these, 100% converted to PCR-

### Table 1

Results of nonrandomized studies with etiological treatment for patients with chronic Chagas disease, showing the relationship between clinical and serological evolution

<table>
<thead>
<tr>
<th>1st author, yr (reference)</th>
<th>No. of patients:</th>
<th>No. of patients (treated/not treated) that had:</th>
<th>% of patients:</th>
<th>Negative for seroconversion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Treated</td>
<td>Not treated</td>
<td>EKG changes</td>
<td>Progression of cardiomyopathy</td>
</tr>
<tr>
<td>Viotti, 1994 (33)</td>
<td>131</td>
<td>70</td>
<td>0/4</td>
<td>2/17</td>
</tr>
<tr>
<td>Gallerano, 2000 (35)</td>
<td>535</td>
<td>668</td>
<td>14/34</td>
<td>4/18</td>
</tr>
<tr>
<td>Viotti, 2006 (37)</td>
<td>283</td>
<td>283</td>
<td>5/16</td>
<td>4/14</td>
</tr>
<tr>
<td>Fabbro De Suasnábar, 2000 (34)</td>
<td>54</td>
<td>57</td>
<td>4/16</td>
<td></td>
</tr>
<tr>
<td>Avg</td>
<td>6/17</td>
<td>3/16</td>
<td></td>
<td>78</td>
</tr>
</tbody>
</table>

* Treatment was with benznidazole except for reference 35, which reports on 309 patients treated with alopurinol, 130 treated with benznidazole, and 96 treated with nifurtimox.
negative immediately after treatment. Additionally, sustained PCR-negative results were observed in 90% of treated patients after 1 year posttreatment. Standardized qualitative PCR for the assessment of the impact of parasitic load on the overall treatment response is now available (43) and is being used in ongoing preclinical and clinical studies. These studies will clarify the value of quantitative and qualitative T. cruzi DNA measurements for monitoring therapeutic response and their association with clinical outcomes (40,41).

Changes in various biochemical (44) and nonconventional serological and immune parameters detected shortly after benznidazole treatment may also be used for evaluating therapeutic efficacy. Following benznidazole treatment, there is a reduction of several markers, such as (i) anti-T cruzi gamma interferon (IFN-γ)-producing cells (45), (ii) T. cruzi antigen-specific antibody titers detected using nonconventional serology (multiplex) (26), and (iii) seroreactivity against specific recombinant antigens (complement regulatory protein, recombinant trans-sialidase, or kinetoplastid antigen) (46,47).

The tools available to assess treatment impact in adult chronic patients, although not always accessible in the medical practice, can be summarized as follows.

- Clinical stability, which has low sensitivity but high significance, should be evaluated using clinical signs and symptoms and complementary methods like EKG and echocardiogram and should always accompany the other markers for treatment efficacy.
- Seroconversion using conventional serology is often long-term or incomplete, although it continues to be a standard for follow-up.
- Changes in specific anti-T. cruzi T cell responses and IFN-γ production after treatment may correlate with the immune status prior to treatment and with the efficacy of treatment.

ADVERSE EFFECTS OF ANTIPARASITIC TREATMENT

Both benznidazole and nifurtimox, the only drugs currently available for treatment, can have variable adverse effects. Adults are more affected than children, and a proportion of treated individuals must discontinue treatment due to severe adverse events (ADRs). Severe adverse events, similar to the incidence of ADR like Stevens-Johnson syndrome for other drugs, occur in an estimated one in 3,000 treated patients (48). Using a rabbit model, a high dose of benznidazole can provoke an increased risk of lymphoma. However, in humans and with the doses used for Chagas treatment, no such risk has been detected in adult cohorts with long-term follow-up (49).

Strict supervision of patients is required to manage ADR with the aforementioned drugs. The risk of adverse effects and lack of experience in ADR prevention and management, especially in adults, often affects physician compliance for treatment (physician opposition). The development of more-effective and safe drugs is a clear target for improved patient outcome and for clinical management. Fortunately, the currently available drugs can be used in all T. cruzi-infected adults at least until 50 years of age with careful follow-up by attending clinical staff.

CONCLUSIONS

Chagas is a major neglected disease. For years, the hypothesis that chronic Chagas disease has an autoimmune origin has held back basic research and the development of more effective antiparasitic drugs and, more importantly, has led to the failure to treat most

![Comparison of concepts belonging to the old and the new paradigms for chronic Chagas disease. Relevant references are given in parentheses.](http://aac.asm.org/)

**FIG 1**
chronic adult patients. The lack of recognition of the important role of parasite persistence for the development of lesions and clinical presentations is only one of the current barriers to more effective clinical management of CD. From an integrated perspective, appropriate follow-up care for chronic patients and the development of clinical trials for new drug candidates will require appropriate early follow-up and surrogate markers for cure. The evidence-based paradigm shift (Fig. 1) that supports etiological treatment of chronic patients will require the development of novel marker tools. Whereas there has been clear recognition of the shift in the treatment paradigm by academia for several years, public health and clinical care communities have lagged in recognizing and adopting this evidence. The greatest challenge now is how to change the mindset and habits of health professionals who are biased by the old paradigm.

ACKNOWLEDGMENT
We declare that we have no conflicts of interest.

REFERENCES


